Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Payables (2016 - 2026)

Pharma-Bio Serv's Payables history spans 16 years, with the latest figure at $2.6 million for Q1 2026.

  • For Q1 2026, Payables rose 171.94% year-over-year to $2.6 million; the TTM value through Jan 2026 reached $2.6 million, up 171.94%, while the annual FY2025 figure was $991169.0, 12.1% down from the prior year.
  • Payables reached $2.6 million in Q1 2026 per PBSV's latest filing, up from $991169.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $2.8 million in Q1 2024 to a low of $874379.0 in Q3 2025.
  • Average Payables over 5 years is $1.5 million, with a median of $1.5 million recorded in 2023.
  • Peak YoY movement for Payables: plummeted 65.83% in 2025, then soared 171.94% in 2026.
  • A 5-year view of Payables shows it stood at $1.6 million in 2022, then decreased by 9.95% to $1.5 million in 2023, then dropped by 23.15% to $1.1 million in 2024, then decreased by 12.1% to $991169.0 in 2025, then skyrocketed by 161.06% to $2.6 million in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Payables are $2.6 million (Q1 2026), $991169.0 (Q4 2025), and $874379.0 (Q3 2025).